Nice copy and paste.
Another reason that they may have found significance is because it was post hoc subgroup analysis.
Which, to be honest, is more likely as that is the only way they have found significance in their RCTs - which is extremely concerning.
This simply means the significance found could be a product of statistics, rather than the treatment being efficacious.
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-417
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |